CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants

Drug Metabolism and Disposition

Volumn 28, Issue 10, 2000, Pages 1176-1183

  Hesse, L M ^a   Venkatakrishnan, K ^a   Court, M H ^a   Von Moltke, L L ^a   Duan, S X ^a   Shader, R I ^a   Greenblatt, D J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CYTOCHROME P450 CYP2B6; DEXTROMETHORPHAN; FLUOXETINE; FLUVOXAMINE; MEPHENYTOIN; NEFAZODONE; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; DEMETHYLATION; DEPRESSION; DOSE RESPONSE; DRUG FORMULATION; DRUG INHIBITION; DRUG TOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; PRIORITY JOURNAL; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION;

ANTIBODIES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOTRANSFORMATION; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; HUMAN; HYDROXYLATION; ISOENZYMES; KINETICS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; PAROXETINE; SERTRALINE; SUPPORT, U.S. GOV'T, P.H.S.; TRIAZOLES;

EID: 0033820249     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Combining serotonin reuptake inhibitors and bupropion in partial responders antidepressant monotherapy
2. ADHD through the life span: The role of bupropion in treatment
3. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes
4. Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation
5. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism
6. Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection
7. Cytochrome P450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes
8. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research
9. Seizures and bupropion: A review
10. Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling
11. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression
12. Further characterization of the expression in liver and catalytic activity of CYP2B6
13. The role of CYP2B6 in human xenobiotic metabolism
14. Assessment of CYP3A4(3A4) contribution to bupropion (B) hydroxylation in human liver microsomes (HLMs) (Abstract)
15. Human CYP2B6: Expression, inducibility and catalytic activities
16. Bupropion in depression.II. The role of metabolites in clinical outcome
17. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes
18. Expression of human cytochrome P450 2B6 in Escherichia coli: Characterization of catalytic activity and expression levels in human liver
19. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin
20. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers
21. A comparison of sustained-release bupropion and placebo for smoking cessation
22. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
23. Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6
24. Role of human CYP2B6 in S-mephobarbital N-demethylation
25. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose
26. Validation of bupropion (B) hydroxylation as a CYP2B6 (2B6) catalytic marker
27. Characterization of cytochrome P-450 2B6 in human liver microsomes
28. Augmentation strategies with serotonergic-noradrenergic combinations
29. Bupropion plasma levels and CYP2D6 phenotype
30. Should bupropion dosage be adjusted based upon therapeutic drug monitoring?
31. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
32. Metabolism and kinetics of bupropion
33. A possible bupropion and imipramine interaction
34. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
35. Human liver CYP2B6-catalyzed hydroxylation of RP 73401
36. Monospecific antipeptide antibody to cytochrome P-450 2B6
37. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4
38. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
39. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver rnicrosomes
40. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion
41. In vitro metabolism of bupropion by human liver microsomes and cDNA expressed human cytochrome P450s